Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01538680




Registration number
NCT01538680
Ethics application status
Date submitted
21/02/2012
Date registered
24/02/2012
Date last updated
29/05/2019

Titles & IDs
Public title
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Scientific title
An Open-label Phase IIIb Study of Regorafenib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy
Secondary ID [1] 0 0
2011-005836-25
Secondary ID [2] 0 0
15967
Universal Trial Number (UTN)
Trial acronym
CONSIGN
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Colorectal Neoplasms 0 0
Condition category
Condition code
Cancer 0 0 0 0
Bowel - Back passage (rectum) or large bowel (colon)

Intervention/exposure
Study type
Expanded Access
Description of intervention(s) / exposure
Treatment: Drugs - Regorafenib (BAY73-4506)

Treatment: Drugs: Regorafenib (BAY73-4506)
Subjects will receive 160 mg regorafenib po every day (qd) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off). Subjects will continue on treatment until at least one of the following occurs (main criteria):

Progressive Disease (PD). The subject may continue treatment at the investigator's discretion.

Death Unacceptable toxicity Subject withdraws consent Treating physician determines discontinuation of treatment is in the subject's best interest Substantial non-compliance with the protocol
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes

Eligibility
Key inclusion criteria
* Male or female subjects 18 years of age
* Life expectancy of at least 3 months
* Histological or cytological documentation of adenocarcinoma of the colon or rectum. All other histological types are excluded.
* Subjects with metastatic colorectal cancer (Stage IV)
* Progression during or within 3 months following the last administration of approved standard therapies which must include fluoropyrimidine, oxaliplatin, irinotecan, bevacizumab and cetuximab/panitumumab (if KRAS WT) (WT: wild type)
* ECOG Performance Status of = 1 (ECOG: Eastern Cooperative Oncology Group)
* Adequate bone marrow, liver and renal function
* Women of childbearing potential and men must agree to use adequate contraception
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Prior treatment with regorafenib
* Congestive heart failure >/= New York Heart Association (NYHA) class 2
* Uncontrolled hypertension (Systolic blood pressure > 140 mmHg or diastolic pressure > 90 mmHg despite optimal medical management)
* Any hemorrhage or bleeding event >/= CTCAE Grade 3 within 4 weeks prior to the start of study medication.
* Persistent proteinuria of CTCAE Grade 3 (>3.5g/24 hours)
* Unresolved toxicity higher than CTCAE (v. 4.0) Grade 1 attributed to any prior therapy/procedure excluding alopecia, hypothyroidism and oxaliplatin induced neurotoxicity </= Grade 2
* Systemic anticancer therapy including cytotoxic therapy, signal transduction inhibitors, immunotherapy, and hormonal therapy during this trial or within 4 weeks (or within 6 weeks for mitomycin C) before starting to receive study medication

Study design
Purpose of the study
Allocation to intervention
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
NO_LONGER_AVAILABLE
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Recruitment hospital [1] 0 0
- Concord
Recruitment hospital [2] 0 0
- St Leonards
Recruitment hospital [3] 0 0
- Woodville South
Recruitment hospital [4] 0 0
- Footscray
Recruitment hospital [5] 0 0
- Parkville
Recruitment postcode(s) [1] 0 0
2139 - Concord
Recruitment postcode(s) [2] 0 0
2065 - St Leonards
Recruitment postcode(s) [3] 0 0
5011 - Woodville South
Recruitment postcode(s) [4] 0 0
3011 - Footscray
Recruitment postcode(s) [5] 0 0
3050 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
District of Columbia
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Iowa
Country [9] 0 0
United States of America
State/province [9] 0 0
Kentucky
Country [10] 0 0
United States of America
State/province [10] 0 0
Louisiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Maine
Country [12] 0 0
United States of America
State/province [12] 0 0
Massachusetts
Country [13] 0 0
United States of America
State/province [13] 0 0
Michigan
Country [14] 0 0
United States of America
State/province [14] 0 0
Minnesota
Country [15] 0 0
United States of America
State/province [15] 0 0
Mississippi
Country [16] 0 0
United States of America
State/province [16] 0 0
Missouri
Country [17] 0 0
United States of America
State/province [17] 0 0
Nebraska
Country [18] 0 0
United States of America
State/province [18] 0 0
Nevada
Country [19] 0 0
United States of America
State/province [19] 0 0
New Hampshire
Country [20] 0 0
United States of America
State/province [20] 0 0
New York
Country [21] 0 0
United States of America
State/province [21] 0 0
North Carolina
Country [22] 0 0
United States of America
State/province [22] 0 0
North Dakota
Country [23] 0 0
United States of America
State/province [23] 0 0
Ohio
Country [24] 0 0
United States of America
State/province [24] 0 0
Oregon
Country [25] 0 0
United States of America
State/province [25] 0 0
Pennsylvania
Country [26] 0 0
United States of America
State/province [26] 0 0
Rhode Island
Country [27] 0 0
United States of America
State/province [27] 0 0
South Carolina
Country [28] 0 0
United States of America
State/province [28] 0 0
Tennessee
Country [29] 0 0
United States of America
State/province [29] 0 0
Texas
Country [30] 0 0
United States of America
State/province [30] 0 0
Virginia
Country [31] 0 0
United States of America
State/province [31] 0 0
Washington
Country [32] 0 0
Austria
State/province [32] 0 0
Oberösterreich
Country [33] 0 0
Austria
State/province [33] 0 0
Steiermark
Country [34] 0 0
Austria
State/province [34] 0 0
Tirol
Country [35] 0 0
Austria
State/province [35] 0 0
Wien
Country [36] 0 0
Belgium
State/province [36] 0 0
Bruxelles - Brussel
Country [37] 0 0
Belgium
State/province [37] 0 0
Edegem
Country [38] 0 0
Belgium
State/province [38] 0 0
Leuven
Country [39] 0 0
Belgium
State/province [39] 0 0
Roeselare
Country [40] 0 0
Canada
State/province [40] 0 0
Alberta
Country [41] 0 0
Canada
State/province [41] 0 0
Ontario
Country [42] 0 0
Canada
State/province [42] 0 0
Quebec
Country [43] 0 0
Czechia
State/province [43] 0 0
Brno
Country [44] 0 0
Czechia
State/province [44] 0 0
Praha
Country [45] 0 0
Denmark
State/province [45] 0 0
Aarhus C
Country [46] 0 0
Denmark
State/province [46] 0 0
Copenhagen
Country [47] 0 0
Finland
State/province [47] 0 0
Helsinki
Country [48] 0 0
Finland
State/province [48] 0 0
HUS
Country [49] 0 0
France
State/province [49] 0 0
Avignon
Country [50] 0 0
France
State/province [50] 0 0
Bordeaux
Country [51] 0 0
France
State/province [51] 0 0
CLERMONT-FERRAND Cedex 1
Country [52] 0 0
France
State/province [52] 0 0
Le Mans Cedex 2
Country [53] 0 0
France
State/province [53] 0 0
Lille Cedex
Country [54] 0 0
France
State/province [54] 0 0
Marseille
Country [55] 0 0
France
State/province [55] 0 0
Montpellier Cedex
Country [56] 0 0
France
State/province [56] 0 0
Nice
Country [57] 0 0
France
State/province [57] 0 0
Paris Cedex 15
Country [58] 0 0
France
State/province [58] 0 0
Paris
Country [59] 0 0
France
State/province [59] 0 0
Reims Cedex
Country [60] 0 0
France
State/province [60] 0 0
Saint Herblain
Country [61] 0 0
France
State/province [61] 0 0
Strasbourg Cedex
Country [62] 0 0
France
State/province [62] 0 0
Toulouse
Country [63] 0 0
Germany
State/province [63] 0 0
Baden-Württemberg
Country [64] 0 0
Germany
State/province [64] 0 0
Bayern
Country [65] 0 0
Germany
State/province [65] 0 0
Niedersachsen
Country [66] 0 0
Germany
State/province [66] 0 0
Nordrhein-Westfalen
Country [67] 0 0
Germany
State/province [67] 0 0
Rheinland-Pfalz
Country [68] 0 0
Germany
State/province [68] 0 0
Sachsen-Anhalt
Country [69] 0 0
Germany
State/province [69] 0 0
Sachsen
Country [70] 0 0
Germany
State/province [70] 0 0
Berlin
Country [71] 0 0
Germany
State/province [71] 0 0
Hamburg
Country [72] 0 0
Greece
State/province [72] 0 0
Heraklion
Country [73] 0 0
Greece
State/province [73] 0 0
Kifissia / Athens
Country [74] 0 0
Hungary
State/province [74] 0 0
Budapest
Country [75] 0 0
Ireland
State/province [75] 0 0
Cork
Country [76] 0 0
Ireland
State/province [76] 0 0
Dublin
Country [77] 0 0
Israel
State/province [77] 0 0
Beer Sheva
Country [78] 0 0
Israel
State/province [78] 0 0
Haifa
Country [79] 0 0
Israel
State/province [79] 0 0
Jerusalem
Country [80] 0 0
Israel
State/province [80] 0 0
Petah Tikva
Country [81] 0 0
Israel
State/province [81] 0 0
Tel Aviv
Country [82] 0 0
Italy
State/province [82] 0 0
Campania
Country [83] 0 0
Italy
State/province [83] 0 0
Emilia-Romagna
Country [84] 0 0
Italy
State/province [84] 0 0
Lazio
Country [85] 0 0
Italy
State/province [85] 0 0
Liguria
Country [86] 0 0
Italy
State/province [86] 0 0
Lombardia
Country [87] 0 0
Italy
State/province [87] 0 0
Marche
Country [88] 0 0
Italy
State/province [88] 0 0
Puglia
Country [89] 0 0
Italy
State/province [89] 0 0
Sicilia
Country [90] 0 0
Italy
State/province [90] 0 0
Toscana
Country [91] 0 0
Italy
State/province [91] 0 0
Veneto
Country [92] 0 0
Mexico
State/province [92] 0 0
Distrito Federal
Country [93] 0 0
Mexico
State/province [93] 0 0
Guanajuato
Country [94] 0 0
Mexico
State/province [94] 0 0
Jalisco
Country [95] 0 0
Mexico
State/province [95] 0 0
Aguascalientes
Country [96] 0 0
Mexico
State/province [96] 0 0
Oaxaca
Country [97] 0 0
Mexico
State/province [97] 0 0
Toluca
Country [98] 0 0
Mexico
State/province [98] 0 0
Veracruz
Country [99] 0 0
Netherlands
State/province [99] 0 0
Amsterdam
Country [100] 0 0
Netherlands
State/province [100] 0 0
Leiden
Country [101] 0 0
Norway
State/province [101] 0 0
Oslo
Country [102] 0 0
Poland
State/province [102] 0 0
Bialystok
Country [103] 0 0
Poland
State/province [103] 0 0
Poznan
Country [104] 0 0
Portugal
State/province [104] 0 0
Coimbra
Country [105] 0 0
Portugal
State/province [105] 0 0
Porto
Country [106] 0 0
Russian Federation
State/province [106] 0 0
Kazan
Country [107] 0 0
Russian Federation
State/province [107] 0 0
Krasnodar
Country [108] 0 0
Russian Federation
State/province [108] 0 0
Moscow
Country [109] 0 0
Russian Federation
State/province [109] 0 0
Obninsk
Country [110] 0 0
Russian Federation
State/province [110] 0 0
Orenburg
Country [111] 0 0
Russian Federation
State/province [111] 0 0
St. Petersburg
Country [112] 0 0
Spain
State/province [112] 0 0
Andalucía
Country [113] 0 0
Spain
State/province [113] 0 0
Barcelona
Country [114] 0 0
Spain
State/province [114] 0 0
Cantabria
Country [115] 0 0
Spain
State/province [115] 0 0
A Coruña
Country [116] 0 0
Spain
State/province [116] 0 0
Madrid
Country [117] 0 0
Spain
State/province [117] 0 0
Málaga
Country [118] 0 0
Spain
State/province [118] 0 0
Sevilla
Country [119] 0 0
Spain
State/province [119] 0 0
Valencia
Country [120] 0 0
Sweden
State/province [120] 0 0
Linköping
Country [121] 0 0
Sweden
State/province [121] 0 0
Uppsala
Country [122] 0 0
Switzerland
State/province [122] 0 0
Basel-Stadt
Country [123] 0 0
Switzerland
State/province [123] 0 0
Graubünden
Country [124] 0 0
Switzerland
State/province [124] 0 0
Bern
Country [125] 0 0
Switzerland
State/province [125] 0 0
Genève
Country [126] 0 0
Switzerland
State/province [126] 0 0
Zürich
Country [127] 0 0
United Kingdom
State/province [127] 0 0
Leicestershire
Country [128] 0 0
United Kingdom
State/province [128] 0 0
Manchester

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Bayer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a phase III B, prospective, interventional, open-label, single-arm, multicenter study to provide regorafenib to subjects diagnosed with metastatic colorectal cancer who have failed after standard therapy and for whom no therapy alternatives exist, in the time between positive results and approval / availability on the market, and to collect safety data for regorafenib until market access.

Regorafenib is an oral (i.e. taken by mouth) multi-targeted kinase inhibitor. A kinase inhibitor targets certain key proteins that are essential for the survival of the cancer cell. By specifically targeting these proteins, regorafenib may stop cancer growth. The growth of the tumor may be decreased by preventing these specific proteins from functioning.

The primary endpoint of this study will be safety.
Trial website
https://clinicaltrials.gov/study/NCT01538680
Trial related presentations / publications
Van Cutsem E, Martinelli E, Cascinu S, Sobrero A, Banzi M, Seitz JF, Barone C, Ychou M, Peeters M, Brenner B, Hofheinz RD, Maiello E, Andre T, Spallanzani A, Garcia-Carbonero R, Arriaga YE, Verma U, Grothey A, Kappeler C, Miriyala A, Kalmus J, Falcone A, Zaniboni A. Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study. Oncologist. 2019 Feb;24(2):185-192. doi: 10.1634/theoncologist.2018-0072. Epub 2018 Sep 6.
Public notes

Contacts
Principal investigator
Name 0 0
Bayer Study Director
Address 0 0
Bayer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01538680